Migraine

Study results show that an individual received little or no relief from doing yoga, eliminating certain foods, practicing medication, or taking prescribed medications.

Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Previous research has shown that genetic factors contribute immensely to the risk of migraine.

Galcanezumab-gnlm (Emgality) is indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.

Headache disorders most affect the ability to do physical labor, decision-making skills, and memory, investigators from the University of Copenhagen say.

Although the risks are still, individuals with a history of migraines should be aware of and consult with their physicians, investigators say.

Pharmacists must understand the value of monitoring changes in quality of life and headache frequency to help facilitate the decision to continue, discontinue, or restart migraine prophylaxis.

Erenumab (Aimovig) was the first anti-CGRP agent approved by the FDA for migraine prophylaxis.

Nerivio is the first FDA-cleared smartphone-controlled prescribed wearable device for the acute treatment of migraine.

The FDA has approved atogepant oral tablets (Qulipta; AbbVie) for the preventive treatment of episodic migraines in adults.

Nurtec is the first oral calcitonin gene-related peptide antagonist approved for both acute and preventative treatment of migraine.

Physicians advised the individual to adopt the Low Inflammatory Foods Everyday (LIFE) diet, which is a nutrient dense, whole food, plant-based diet.

Tosymra is indicated for the acute treatment of migraine with or without aura in adults.

Pharmacists can encourage patients to ask prescribers about newly approved preventive therapies when appropriate.

Patients were randomized 1:1 to receive either erenumab or topiramate, with the erenumab arm split into dosages of 70 mg or 140 mg.

Individuals taking erenumab had a 55.4% reduction from baseline in their monthly migraine days, results from HER-MES show.

Ten quiz questions to assess your knowledge on common symptoms and treatments for migraine headaches.

Atogepant is indicated for the preventive treatment of episodic migraine in adults.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Migraine headaches can be caused by triggers such as hormonal changes, drinks, stress, sensory stimuli, sleep changes, physical factors, weather changes, medications, foods, and food additives.

The nasal spray bypasses the gut and potential absorption issues associated with it, and offers consistent relief even when administered hours after the onset of a migraine attack.

A greater proportion of atogepant-treated participants achieved at least a 50% reduction in mean monthly migraine days.

Peptides that cause migraine pain can influence insulin production in mice, possibly by regulating the amount of secreted insulin or by increasing the number of pancreatic cells that produce it.